MATTERHORN
Regimen
- Experimental
- durvalumab 1500 mg q4w + perioperative FLOT, then durvalumab q4w x10
- Control
- placebo q4w + perioperative FLOT, then placebo q4w x10
Population
Resectable gastric/GEJ adenocarcinoma
Key finding
2y EFS 67.4% vs 58.5% (HR 0.71, 95% CI 0.58-0.86, P<0.001); pCR 19.2% vs 7.2% (RR 2.69); 2y OS 75.7% vs 70.4%
Source: PMID 40454643
Timeline
Guideline citations
- NCCN GASTRIC (p.4)
- CSCO GASTRIC 2025 (p.67)⚠️ OCR source